Medicare overpaid suppliers $92.5M for inhalation drugs, inspector general finds

(By Maia Anderson for Becker’s Hospital Review)

The HHS’ Office of Inspector General found that Medicare overpaid suppliers of inhalation drugs by $92.5 million in 2017.

The OIG’s review, published Oct. 31, notes that the top three inhalation drug suppliers received 56 percent of total Medicare payments in 2017. A prior OIG review found that the top two suppliers of inhalation drugs generally complied with Medicare requirements, and the third was found to have some billing issues. However, the goal of this review was to determine if the billing issues were primarily caused by the suppliers that received the other 44 percent.  Continue reading article here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.